This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
EAN 2026: New Fintepla data in Dravet Syndrome and LGS
The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia.
By Pharmaceutical Technology
· Jun 30, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induc…
The WeekFierceBiotech ↗
Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmace…
The WeekBriefing
Norwich Pharmaceuticals wins FDA approval for generic baloxavir marboxil, expanding affordable access to one-d…